883554-96-9 Usage
Description
(2-Pyrrolidin-1-yl-2-oxo-ethyl)-carbamic acid tert-butyl ester is a carbamic acid derivative featuring a pyrrolidin-1-yl group and a tert-butyl ester group. (2-PYRROLIDIN-1-YL-2-OXO-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER serves as a versatile intermediate in the synthesis of pharmaceuticals and agrochemicals, and also holds potential as a reactive intermediate in organic synthesis and a building block for the preparation of various compounds. Careful handling and adherence to safety protocols are essential when working with this chemical in a laboratory setting.
Uses
Used in Pharmaceutical Synthesis:
(2-Pyrrolidin-1-yl-2-oxo-ethyl)-carbamic acid tert-butyl ester is used as an intermediate for the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, (2-Pyrrolidin-1-yl-2-oxo-ethyl)-carbamic acid tert-butyl ester is utilized as an intermediate in the production of pesticides and other agrochemicals, contributing to the creation of effective solutions for agricultural challenges.
Used in Organic Synthesis:
As a reactive intermediate, (2-Pyrrolidin-1-yl-2-oxo-ethyl)-carbamic acid tert-butyl ester is employed in organic synthesis for the preparation of a wide range of organic compounds, expanding the scope of chemical research and development.
Used in Building Blocks for Compound Preparation:
(2-PYRROLIDIN-1-YL-2-OXO-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER also serves as a building block for the preparation of various compounds, providing a foundation for the creation of complex molecules with diverse applications across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 883554-96-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,3,5,5 and 4 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 883554-96:
(8*8)+(7*8)+(6*3)+(5*5)+(4*5)+(3*4)+(2*9)+(1*6)=219
219 % 10 = 9
So 883554-96-9 is a valid CAS Registry Number.
InChI:InChI=1/C11H20N2O3/c1-11(2,3)16-10(15)12-8-9(14)13-6-4-5-7-13/h4-8H2,1-3H3,(H,12,15)
883554-96-9Relevant articles and documents
PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE
-
Paragraph 1052, (2020/07/07)
The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:
AZOLE-SUBSTITUTED PYRIDINE COMPOUND
-
Paragraph 0700; 0701, (2019/01/08)
The present invention provides a compound represented by formula [I'| shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme, wherein the structure represented by formula [III] shown below represents any of the structures represented by formula group [IV] shown below, wherein R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3alkanediyl, or the formula -O-CH2CH2-; and ring A represents (a) substituted C4-6cycloalkyl, (b) substituted 4- to 6-membered saturated nitrogen-containing heterocyclyl, (c) substituted phenyl, (d) substituted pyridyl, (e) substituted 2,3-dihydrobenzofuran, (f) 4- to 6-membered saturated oxygen-containing heterocyclyl, etc.
Design and synthesis of novel diamide derivatives of glycine as antihyperglycemic agents
Sharma, Radhika,Soman, Shubhangi S.
supporting information, p. 1307 - 1317 (2016/08/16)
DPP-4 inhibition is one of the most extensively explored approaches for the management of type 2 diabetes (T2D). Most DPP-4 inhibitors in the market contain a proline mimetic active pharmacophore. Herein, we report the design, synthesis, and preliminary e
